Press Releases
Phillips 66 (NYSE: PSX) today announced it has closed the sale of a 65 percent interest in its Germany and Austria retail marketing business to a consortium owned by subsidiaries of Energy Equation Partners and Stonepeak. Phillips 66 will retain a 35 percent non-operated interest in the new joint venture company which will hold the retail marketing business.
By Phillips 66 · Via Business Wire · December 1, 2025
Engine Capital LP (together with its affiliates, “Engine” or “we”), a top five independent common stock shareholder of UniFirst Corporation (NYSE: UNF) (“UniFirst” or the “Company”) with ownership of approximately 3.2% of the Company’s outstanding shares of common stock, today released an open letter to the Company’s independent directors: Joseph M. Nowicki, Sergio A. Pupkin, Raymond C. Zemlin, Cecilia McKenney, and Michael Iandoli.
By Engine Capital LP · Via Business Wire · December 1, 2025
SAGA Diagnostics, a pioneer in blood-based cancer detection and precision medicine redefining the standard for ultra-sensitive and early molecular residual disease (MRD) detection, will present five posters—three new studies and two trials in progress—at the 2025 San Antonio Breast Cancer Symposium (SABCS), December 9-12, 2025 in San Antonio, TX.
By SAGA Diagnostics · Via Business Wire · December 1, 2025
Bank Credit Defaults Fall, But Market Risk Grows
Via ACCESS Newswire · December 1, 2025
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for its subsidiary Xeris Pharmaceuticals Inc.’s U.S. patent application covering XP-8121, one of its novel product candidates. The Notice of Allowance indicates that the USPTO has determined the application meets the requirements for patentability and is expected to issue as a U.S. patent following standard administrative steps. The allowed claims in this application are specific to the XP-8121 formulation. In parallel, Xeris continues to pursue additional layers of U.S. and international IP protection in the levothyroxine (LT4) technology space.
By Xeris Biopharma Holdings, Inc. · Via Business Wire · December 1, 2025
Novocure (NASDAQ: NVCR) today announced the appointment of Frank Leonard as Chief Executive Officer (CEO), effective immediately. Mr. Leonard previously served as President of Novocure and succeeds Ashley Cordova who has resigned from the company.
By Novocure · Via Business Wire · December 1, 2025
Great Hill Partners, a private equity firm that invests in high‑growth, disruptive companies, today announced that Jonathan Bank has joined the firm’s Growth Team as Head of Revenue Operations.
By Great Hill Partners · Via Business Wire · December 1, 2025
GeoPark Limited (“GeoPark” or the “Company”) (NYSE: GPRK), a leading independent energy company with over 20 years of successful operations across Latin America, today announced its 2026 Work Program (the “Program”) and 2027-2028 guidelines, which have been approved by the Company’s Board of Directors (the “Board”).
By GeoPark Limited · Via Business Wire · December 1, 2025
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to olezarsen as an adjunct to diet to reduce triglyceride (TG) levels in adults with severe hypertriglyceridemia (sHTG) (TG greater than or equal to 500 mg/dL). Breakthrough Therapy designation is intended to expedite the review of medicines that treat a serious or life-threatening condition and have shown preliminary clinical evidence indicating the potential for substantial improvement over available therapies.
By Ionis Pharmaceuticals, Inc. · Via Business Wire · December 1, 2025
Vertical Aerospace (“Vertical” or “Company”) [NYSE:EVTL] today announced that 16 members of its Board of Directors and senior leadership team completed open-market purchases of the Company’s ordinary shares over a two-week open trading window period in November 2025.
By Vertical Aerospace · Via Business Wire · December 1, 2025
Spanish Mountain Gold Ltd. (the "Company" or "Spanish Mountain Gold") (TSX-V: SPA) (FSE: S3Y) (OTCQB: SPAUF) is pleased to provide additional assay results from exploration drill holes 25-DH-1297, 25-DH-1298, and 25-DH-1299 that were completed as part of its 2025 Fall Diamond Drill program (“2025 Fall Drill Program”) for the Spanish Mountain Gold (“SMG”) project, which is located in the Cariboo Gold Corridor, British Columbia, Canada.
By Spanish Mountain Gold Ltd. · Via Business Wire · December 1, 2025
Coalition, the world's first Active Insurance provider designed to help prevent digital risk before it strikes, today announced the appointment of Frank Fumarola as the company’s new Chief Product Officer.
By Coalition · Via Business Wire · December 1, 2025
MONTREAL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Brunswick Exploration Inc. (TSX-V: BRW, OTCQB: BRWXF; “BRW” or the “Company”) is pleased to announce more results from its inaugural drilling campaign at the Anatacau Main Project, located in the Eeyou Istchee-James Bay region of Quebec. All results have now been received and cement BRW’s latest discovery within its growing portfolio as a high priority target for follow-up drilling.
By Brunswick Exploration · Via GlobeNewswire · December 1, 2025
TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Barrick Mining Corporation (NYSE:B)(TSX:ABX) (“Barrick” or the “Company”) today announces that the Company’s Board of Directors has unanimously authorized Barrick’s management team to explore an initial public offering (“IPO”) of a subsidiary that will hold Barrick’s premier North American Gold Assets (“NewCo”).
By Barrick Mining Corporation · Via GlobeNewswire · December 1, 2025
LONDON, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Marex Group plc (‘Marex’ or the ‘Group’; NASDAQ: MRX), the diversified global financial services platform, today announces that it has completed the acquisition of UK equity market maker Winterflood Securities (“Winterflood”). Marex further announces it has entered into a conditional agreement to sell Winterflood’s custody business, Winterflood Business Services (“WBS”), to Epiris Fund III, advised by Epiris LLP (“Epiris”), a UK private equity firm. WBS provides outsourced dealing, settlement and custody services to a diverse range of clients.
By Marex Group plc · Via GlobeNewswire · December 1, 2025
TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Highlander Silver Corp. (TSX: HSLV; “Highlander Silver” or the “Company”) is pleased to report exceptional assay results from shallow drilling at its expanding Bonita vein system. These results include the highest grades reported to date and the discovery of a new zone in step-out drilling over 200m northwest of prior holes along trend. The Bonita vein system is exposed along a ridgeline approximately 10km to the south of the bonanza grade Ayelen deposit at the San Luis gold-silver project in Central Peru.
By Highlander Silver Corp. · Via GlobeNewswire · December 1, 2025
New analysis highlights how congestion around major U.S. airports changed during the federal shutdown and key holiday travel periods
By TomTom International BV US · Via GlobeNewswire · December 1, 2025
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates overall response rate and safety profile consistent with the 1500mg QW dose
By Bicara Therapeutics Inc. · Via GlobeNewswire · December 1, 2025
IRVINE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer will participate in a fireside chat at the upcoming 37th Annual Piper Sandler Healthcare Conference on Thursday, December 4, 2025 at 8:50 a.m. ET (5:50 a.m. PT).
By Eledon Pharmaceuticals, Inc. · Via GlobeNewswire · December 1, 2025
EMERYVILLE, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Metagenomi, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients, today announced that the Company will present new preclinical data supporting the third target, APOC3, in its collaboration with Ionis Pharmaceuticals at the Nature Conference “Cracking the Code: Nucleic Acid Medicines Coming of Age” taking place December 8-10, 2025, in Boston, MA.
By Metagenomi, Inc. · Via GlobeNewswire · December 1, 2025
TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Inventus Mining Corp. (TSXV: IVS) (“Inventus” or the “Company”) is pleased to report the results from its 007 North bulk sample at its wholly-owned Pardo Gold Project, located 65 km northeast of Sudbury, Ontario.
By Inventus Mining Corp. · Via GlobeNewswire · December 1, 2025
GRAND RAPIDS, Mich., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Edustaff, a leading provider of K-12 educational staffing solutions, is proud to announce a new partnership with Holmdel Township Public Schools in New Jersey. This collaboration marks another key milestone in Edustaff’s continued expansion across the state, supporting schools with high-quality substitute and support staff.
By Edustaff · Via GlobeNewswire · December 1, 2025
TARRYTOWN, N.Y. and SOMERVILLE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) and Tessera Therapeutics, Inc., today announced a global collaboration to develop and commercialize TSRA-196, Tessera’s lead investigational in vivo Gene Writing program for the treatment of alpha-1 antitrypsin deficiency (AATD), an inherited monogenic disease that can affect the lungs, liver, or both organs, and currently impacts approximately 200,000 people in the U.S. and Europe. TSRA-196 is designed to precisely correct the genetic mutation underlying AATD, with the goal of restoring production of functional alpha-1 antitrypsin (AAT) protein through a one-time, durable treatment option for patients. Tessera expects to file an Investigational New Drug and multiple Clinical Trial Applications for TSRA-196 with the U.S. Food and Drug Administration (FDA) by the end of the year.
By Regeneron Pharmaceuticals, Inc. · Via GlobeNewswire · December 1, 2025
Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establishing accuracy as the foundation for downstream discovery
By Seer, Inc. · Via GlobeNewswire · December 1, 2025
BURLINGTON, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of the Company, will be participating in a fireside chat at the 8th Annual Evercore Healthcare Conference, being held December 2-4, 2025, in Coral Gables, FL.
By Fractyl Health, Inc. · Via GlobeNewswire · December 1, 2025
CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced that it has been awarded a Veterans Affairs (VA) Federal Supply Schedule (FSS) contract, effective December 1, 2025. The first product listed on the FSS is the IB-Stim®, a drug-free treatment for functional abdominal pain in patients 8 years and older. This contract award establishes NeurAxis as a federal contractor and creates a clear commercial pathway into the VA health system, which serves nearly 7 million active patients annually. The Company expects the VA award, combined with broadening reimbursement and increasing clinical adoption, to support sustained commercial momentum entering 2026.
By NeurAxis, Inc. · Via GlobeNewswire · December 1, 2025
TORONTO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma”), is pleased to announce that national television network CTV News’ flagship investigative program W5 has aired the final segment, Part Three, of their three-part series about Quantum Biopharma and the company’s allegations of stock market manipulation.
By Quantum BioPharma · Via GlobeNewswire · December 1, 2025
NEW YORK, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that Michael A. Metzger, Chief Executive Officer, will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on Thursday, December 4, 2025, at 11:15 a.m. ET.
By Syndax Pharmaceuticals, Inc. · Via GlobeNewswire · December 1, 2025
~ Gross margin expected to increase from 39.6% to 50.5% ~
By Mobix Labs, Inc. · Via GlobeNewswire · December 1, 2025
Cambridge, Massachusetts, Dec. 01, 2025 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (Nasdaq: PMN), a clinical-stage biotechnology company developing next-generation therapies for Alzheimer’s disease (AD) and other neurodegenerative disorders, today announced that Neil Warma, Chief Executive Officer of ProMIS Neurosciences, will be participating in a fireside chat and investor one-on-one meetings at the 8th Annual Evercore Healthcare Conference on Tuesday, December 2nd, 2025.
By ProMIS Neurosciences Inc. · Via GlobeNewswire · December 1, 2025
Investment to support the continued evaluation and redevelopment of KALA’s product candidates and patent portfolio, and provide working capital and funding for a potential future strategic transaction
By KALA BIO, Inc. · Via GlobeNewswire · December 1, 2025
LONDON and GAITHERSBURG, Md., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today announced the appointment of Ryan Richardson to the Company’s Board of Directors. Mr. Richardson brings more than 20 years of strategy and corporate development experience and in the healthcare and investment banking industries to Autolus’ Board.
By Autolus Therapeutics plc · Via GlobeNewswire · December 1, 2025
Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients
By Cullinan Therapeutics, Inc. · Via GlobeNewswire · December 1, 2025
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of more than 95 data disclosures, including 27 oral presentations, across company-sponsored studies and external collaborations at the 67th American Society of Hematology (ASH) Annual Meeting, representing exciting advancements in the company’s next-generation hematology portfolio.
By Bristol Myers Squibb · Via Business Wire · December 1, 2025
The "Nitrous Oxide (CAS 10024-97-2) Industry Research 2025: Global and Regional Market Trends 2019-2024 and Forecast to 2029" report has been added to ResearchAndMarkets.com's offering.
By Research and Markets · Via Business Wire · December 1, 2025
USA Compression Partners, LP (NYSE: USAC) (“USAC” or “USA Compression” or the “Partnership”) today announced it has entered into a definitive agreement to acquire J-W Power Company, a large privately-held provider of compression services in the United States, for total consideration of approximately $860 million.
By USA Compression Partners, LP · Via Business Wire · December 1, 2025
TriplePoint Venture Growth BDC Corp. (NYSE: TPVG) (the “Company,” “TPVG,” “we,” “us,” or “our”), a leading financing provider to venture growth stage companies backed by a select group of venture capital firms in technology and other high growth industries, today announced that on November 25, 2025, it entered into an amendment to its revolving credit facility (“Credit Facility”) that, among other things, extends the revolving period to November 30, 2027 and the scheduled maturity date to May 30, 2029, and provides improved terms, including, but not limited to, a reduced spread on borrowings and higher advance rates on assets pledged to the borrowing base. The Company currently has $300 million in total commitments available under the Credit Facility, which includes an accordion feature that allows the Company to increase the size of the Credit Facility to up to $400 million under certain circumstances.
By TriplePoint Venture Growth BDC Corp. · Via Business Wire · December 1, 2025
Dollar General (NYSE: DG) is making holiday celebrations more affordable with its 24 Days of Savings sales event. This December 1st – 24th, shoppers can enjoy a new mega deal every day, making it easier than ever to check off holiday lists while stretching budgets.
By Dollar General · Via Business Wire · December 1, 2025
Exelon Corporation (Nasdaq: EXC) today announced that it intends to offer, subject to market and other conditions, $900 million aggregate principal amount of its convertible senior notes due 2029 in a private placement under the Securities Act of 1933, as amended (the “Securities Act”). Exelon also intends to grant to each of the initial purchasers of the convertible notes an option to purchase, within a 13-day period from, and including, the date on which the convertible notes are first issued, up to an additional $100 million aggregate principal amount of the convertible notes.
By Exelon Corporation · Via Business Wire · December 1, 2025
SCOTTSDALE, AZ, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Signing Day Sports, Inc. (“Signing Day Sports” or the “Company”) (NYSE American: SGN), the developer of the Signing Day Sports app and platform dedicated to improving the recruiting process for high school athletes and college coaches, today announced the public filing of a Registration Statement on Form S-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) by BlockchAIn Digital Infrastructure, Inc. (“BlockchAIn”), a newly formed Delaware corporation created for the purpose of consummating the Company’s previously announced business combination with One Blockchain LLC (“One Blockchain”). The filing follows the Company’s confidential submissions of drafts of the Registration Statement with the SEC on July 8, 2025, August 28, 2025, and September 24, 2025.
By Signing Day Sports, Inc. · Via GlobeNewswire · December 1, 2025
Recognized for helping real estate investors operate stronger businesses, RentRedi’s smart payments, automated workflows, and data-driven insights are built to support growth, wealth building, and financial freedom
By RentRedi · Via GlobeNewswire · December 1, 2025
VANCOUVER, BC / ACCESS Newswire / December 1, 2025 / Northern Dynasty Minerals Ltd. (TSX:NDM)(NYSE American:NAK) ("Northern Dynasty" or the "Company") and its 100%-owned U.S.-based subsidiary Pebble Limited Partnership ("Pebble Partnership") announce that the National Mining Association ("NMA"), the American Exploration & Mining Association ("AEMA"), the Alaska Mining Association ("AMA") and the U.S. Chamber of Commerce (the "Chamber") have filed Amicus Briefs in the Alaska Federal Court in support of one of the largest undeveloped copper projects in the world, located in the U.S., which is being blocked by an illegal Obama/Biden veto.
Via ACCESS Newswire · December 1, 2025
Bullish, an institutionally focused global digital asset platform that provides market infrastructure and information services, is pleased to announce the appointment of Jay Yarow as President, CoinDesk Insights.
By Bullish · Via Business Wire · December 1, 2025
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced plans to present first-in-human data for MK-2214 and MK-1167 at Clinical Trials on Alzheimer’s Disease (CTAD) 2025 in San Diego, California from Dec. 1-4. In addition, the company announced that MK-2214, a novel candidate targeting the abnormal accumulation and aggregation of tau in the brain, has been granted Fast Track Designation by the U.S. Food and Drug Administration for the treatment of Alzheimer’s disease. Fast Track is a process designed to facilitate the development and expedite the review of drug candidates to treat serious conditions and address an unmet medical need.
By Merck Sharp & Dohme · Via Business Wire · December 1, 2025
Spire Global, Inc. (NYSE: SPIR) (“Spire” or “the Company”), a global provider of space-based data, analytics and space services, announced that Deloitte has contracted with them to design, build and operate eight satellites.
By Spire Global, Inc. · Via Business Wire · December 1, 2025
Acquisition of an essential industrial technology provider to the packaging industry
By Brookfield Business Partners · Via GlobeNewswire · December 1, 2025
Wallbox (NYSE: WBX), a global leader in EV charging and energy management solutions, has reached an indicative commercial agreement (“Commercial Agreement”) with its core banking partners and its major shareholders, which contemplates an extension of debt maturities and a proposed liquidity injection of €22.5 million through a combination of debt and equity, to provide a renewed capital structure for the company.
By Wallbox · Via Business Wire · December 1, 2025
Kodiak Gas Services, Inc. (NYSE: KGS) (“Kodiak” or the “Company”) today announced the underwritten public offering (the “Offering”) of 9,762,573 shares of its common stock by Frontier TopCo Partnership, L.P. (the “Selling Stockholder”), an affiliate of the funds known as EQT Infrastructure III and EQT Infrastructure IV. Kodiak will not sell any shares of its common stock in the Offering and will not receive any proceeds from the sale of the shares of its common stock being offered by the Selling Stockholder. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed.
By Kodiak Gas Services, Inc. · Via Business Wire · December 1, 2025
FUZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- The 3rd Overseas Chinese Talent Conference for Development, hosted by the All-China Federation of Returned Overseas Chinese (ACFROC) and the Fujian provincial government, and organized by the Fujian Provincial Federation of Returned Overseas Chinese and the Fuzhou municipal government, unveiled in the city of Fuzhou, capital of east China's Fujian Province on December 1, 2025.
By Office of the Organizing Committee of the 3rd Overseas Chinese Talent Conference for Development · Via GlobeNewswire · December 1, 2025
TORONTO, ON / ACCESS Newswire / December 1, 2025 / Jaguar Mining Inc. ("Jaguar" or the "Company") (TSX:JAG) today is pleased to announce the commencement of drilling activities at the Chamé target, located three kilometres southeast of the Santa Isabel mine within the Company's Paciência complex in Brazil's prolific Iron Quadrangle. Drilling began on November 21, 2025, with the first phase comprising 12 drill holes totaling 3,040 meters. The program is designed to evaluate the potential for a near-surface, open-pittable operation and is part of the Company's five-year Exploration Plan (see Jaguar Mining press release dated September 8, 2025).
Via ACCESS Newswire · December 1, 2025
